FALLOPIAN TUBE CANCER

This study tested a combination of three drugs (nivolumab, bevacizumab, and rucaparib) in 72 people whose ovarian, fallopian tube, or peritoneal cancer had returned after standard treatment. The goal was to see if the combination could shrink tumors or slow cancer growth. While t…

This study was designed to test an experimental drug called BAT8006 in people with ovarian cancer that no longer responds to platinum-based chemotherapy. The goal was to find a safe dose and see if the drug could shrink tumors. However, the study was withdrawn before any particip…

This early-stage study tests an experimental drug called BL-M17D1 in 120 adults with advanced solid tumors that have a specific protein (HER2) or a HER2 gene change. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants mus…

This study tests whether the drug bevacizumab (Avastin) can help control ovarian, fallopian tube, or primary peritoneal cancer that was still found during a second-look surgery. About 35 adults with advanced-stage cancer who already had standard chemotherapy and surgery will rece…

This early-phase study tests a new drug called IMGN151 in 256 adults with recurrent gynaecological cancers (ovarian, endometrial, cervical, and related cancers). The drug is designed to target and kill cancer cells while sparing healthy ones. The main goals are to check safety, f…

This study tests whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) works better than nivolumab alone for people with advanced clear cell ovarian, fallopian tube, or peritoneal cancer. About 46 participants will receive either one or both drugs to see if …

This study tests whether combining a cancer vaccine (DPX-Survivac) with an immunotherapy drug (pembrolizumab) and low-dose chemotherapy can shrink tumors in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The vaccine trains the immune system to attack …

This study tests whether a new drug (ONC-392) combined with an existing immunotherapy (pembrolizumab) can shrink tumors or slow disease in people with ovarian cancer that no longer responds to platinum chemotherapy. About 58 adults with high-grade serous ovarian, primary peritone…

This study tests a new treatment called IMNN-001, a gene therapy given directly into the abdomen, combined with standard chemotherapy for people newly diagnosed with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if the combination helps people…

This early-stage trial tests a new treatment called FT536 for people with ovarian, fallopian tube, or primary peritoneal cancer that has returned after prior therapy. The treatment is given directly into the abdomen three times in one week, after a short course of chemotherapy to…

This study tests a new daily pill called sovilnesib for people with advanced ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to find the safest and most effective dose. About 120 participants will receive different doses to measure side effects an…

This early-phase study tests a new drug, AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment for people with advanced solid tumors that have stopped responding to standard therapies. The main goal is to find the safest dose and check for…

This study tests a two-step treatment for a type of ovarian cancer that has come back after initial chemotherapy. First, patients receive a standard chemo drug (carboplatin) plus a targeted drug (mirvetuximab soravtansine) that attacks cancer cells with a specific marker (FRα). T…

This early study looks at whether taking low-dose aspirin for two weeks before surgery can change the cells and immune environment in the fallopian tubes. Researchers want to see if these changes might lower the risk of developing fallopian tube cancer. The study involves 18 wome…

This study tests a program called Journey Ahead that helps women with gynecologic cancers (like ovarian, endometrial, or cervical cancer) improve their coping and communication skills. About 30 women who have been diagnosed or had a recurrence in the past 5 years will take part. …

This study looks at a fast way to identify depression in women with ovarian, peritoneal, or fallopian tube cancer. It also compares a special support program with enhanced standard care to see which better improves quality of life. About 409 women on active treatment took part. T…

This study looks at 100 women with breast or gynecological cancer to see if their diet before starting chemotherapy affects levels of a protein called hepcidin. Researchers want to know if hepcidin levels are linked to how much of the planned chemotherapy dose patients actually r…

This study tests whether a reminder sent to doctors can increase the number of women with suspicious ovarian masses who are referred to a gynecologic oncologist within 30 days. The study includes 20 women aged 18 and older with a suspicious mass found on imaging. Researchers will…

This pilot study tested whether a prehabilitation program—a set of exercises and health support before surgery—is practical and helpful for 22 women with advanced ovarian cancer. Participants received the program while undergoing chemotherapy to prepare for tumor-removal surgery.…